(DXR) Daxor - Ratings and Ratios

Daxor Corporation (NASDAQ:DXR) is a medical technology firm specializing in blood volume measurement solutions. The companys flagship product, the BVA-100 Blood Volume Analyzer, provides precise, objective quantification of blood volume and composition, enabling clinicians to make data-driven decisions in various medical and surgical contexts. Originally incorporated in 1971 as Idant Corporation, the company rebranded as Daxor Corporation in 1973. Headquartered in Oak Ridge, Tennessee, Daxor operates as a subsidiary of the Estate of Joseph Feldschuh. Its technology addresses a critical gap in patient care by offering standardized, patient-specific blood volume analysis, which is essential for optimizing fluid management and improving outcomes in critically ill patients.

From a financial perspective, Daxor operates with a market capitalization of $36.59 million, reflecting its status as a small-cap company. The stock currently trades at $7.77, with a price-to-earnings ratio of 6.52, indicating a lower valuation compared to industry peers. The companys price-to-book ratio of 1.13 suggests that its stock is moderately aligned with its book value. However, the elevated price-to-sales ratio of 237.29 highlights the markets expectations for future growth relative to current revenue. Daxors return on equity of 7.75% demonstrates modest profitability, though this figure is influenced by its small scale and specialized focus.